-
Exemestane, sold
under the
brand name
Aromasin among others, is a
medication used to
treat breast cancer. It is a
member of the
class of antiestrogens...
-
exemestane.
Exemestane went
through clinical trials in the 1990s and
received FDA
approval in 1999,
marketed as Aromasin.
Indication for
exemestane is...
-
approved to
treat breast cancer:
Irreversible steroidal inhibitors, such as
exemestane (Aromasin),
forms a
permanent and
deactivating bond with the aromatase...
- (everolimus) to
exemestane therapy against advanced breast cancer can
significantly improve progression-free
survival compared with
exemestane therapy alone...
-
gynecomastia in males.
Aromatase inhibitors, such as anastrozole, letrozole,
exemestane, etc., can help to
prevent the
subsequent estrogenic activity of testosterone...
- (INN)
Exblifep Excede Excedrin Excenel Excenel RTU EZ
Exelderm Exelon exemestane (INN)
exenatide (USAN)
exepanol (INN)
Exforge Exforge HCT
Exidine exifone...
-
nisoldipine (Sular) and
nitrendipine (Bayotensin)
Erlotinib (Tarceva)
Exemestane, aromasin, and by
extension all estrogen-like
compounds and aromatase...
- or triptorelin) and
aromatase inhibitors (anastrozole, letrozole, or
exemestane)
slightly improves survival, but has more
severe side effects. Side effects...
-
professional sports which forbids aromatase inhibitors. A
related agent is
exemestane (Aromasin).
Covey DF, Hood WF (April 1981). "Enzyme-generated intermediates...
-
Formestane L02BG03
Anastrozole L02BG04
Letrozole L02BG05
Vorozole L02BG06
Exemestane L02BX01
Abarelix L02BX02
Degarelix L02BX03
Abiraterone L02BX04 Relugolix...
